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LETTERS TO THE EDITOR
Myocardial Salvage,
AT1-Receptor Blockade, AT2-Receptor
Activation and Coronary Collaterals
The article by Jalowy et al. (1) supports the hypothesis that the
cardioprotective effect of AT1-receptor blockade involves angio-
tensin II-induced AT2-receptor activation, bradykinin and pros-
taglandins. This vascular mechanism (AT1-receptor activation
mediates proliferation and vasoconstriction, and AT2-receptor
activation opposes these) might be especially important in patients
with heart failure where AT2-receptors are dominant (2). The
authors insightfully highlighted the conflicting results of AT1-
blockade in different experimental models (1). Unfortunately, they
confused AT1- and AT2-receptors (page 1787, second column,
second paragraph, lines 3 to 11; page 1792, first column, line 7)
and made erroneous statements about AT1- and AT2-receptor
activation and blockade. Thus, on page 1787, AT2-receptor
activation (not AT1) increases kinin formation in isolated dog
coronary arteries; attenuation of left ventricular dilatation after
myocardial infarction in rats by AT1-receptor blockade is abol-
ished by AT2-receptor blockade (not AT1); a kinin-mediated
mechanism secondary to activation of the AT2-receptor may
contribute to cardioprotection achieved by AT1-receptor blockade
(not AT2).
The finding of a dramatic reduction in infarct size after only
30 min of pretreatment with intravenous candesartan (an AT1-
receptor antagonist) in an in vivo, anesthetized minipig model of
90-min “low-flow ischemia” and 120-min reperfusion (1) also
confirms reports of in vitro evidence of cardioprotection after
chronic pretreatment (.30 min) with AT1-receptor antago-
nists. However, patient groups in whom benefits of pretreat-
ment might be applicable need to be identified and studied.
One such group is the hypertensive patient who is prone to
develop an acute coronary syndrome and who is already on an
AT1-receptor blocker.
The authors (1) did not mention that dramatic myocardial
salvage and limitation of early remodeling with the AT1-receptor
antagonist L-158,809, given intravenously for 48 h (0.1 mg/kg
bolus and 0.6 mg/kg/min infusions) after anterior myocardial
infarction in the in vivo dog model, has already been reported (3).
However, Jalowy et al. (1) elegantly produced coronary hypoper-
fusion in the minipig by adjusting a roller pump to reduce systolic
thickening (ultrasonic crystals) by .90%. Although they measured
transmural flow (radioactive microspheres) in samples from the site
of the crystals, their finding of decreased infarct size (albeit using
the TTC [triphenyl tetrazolium chloride] technique) (1) under-
scores the cardioprotective effect of AT1-receptor blockade in
models of low-flow ischemia (in dogs). It is pertinent that a pig
heart has poorly developed collaterals (resembling patients without
longstanding coronary disease or ischemia) so that acute coronary
occlusion results in no reflow ischemia (4). In contrast, a dog heart
has a rich collateral supply (resembling patients with longstanding
coronary disease and ischemia) so that acute coronary occlusion
results in low-flow ischemia (5). The argument that low-flow
allowed the drugs (PD 123,319 i.c., HOE-140 i.c. and indometh-
acin i.v. given before and during ischemia) to reach the ischemic
zone in their modified minipig model (1) is therefore probably
valid. However, because Jalowy et al. (1) only report transmural
flow after 90-min ischemia but not flow (or hemodynamics) after
120 min of reperfusion, one cannot be certain of “reflow” or
“no-reflow” in their model.
The demonstration of a decrease in slope of the relation between
flow after 5 min of ischemia and subsequent infarct size (as percent
of risk region) with candesartan (1) is interesting. However, a
similar effect between flow after 90-min ischemia and 120-min
reperfusion (when infarct size was measured) would have been
more convincing. Demonstration of a reduction of the slope of the
relation between infarct size (after ischemia and reperfusion) and
the risk region (6) would have provided definitive evidence of
myocardial salvage with candesartan.
Jalowy et al. also hinted on the converse hypothesis (page 1792,
first column) whereby AT2-receptor blockade might redistribute
AngII toward AT1-receptors and cause their activation (1). How-
ever, AT2-receptor blockade with PD 123,319 did not increase
infarct size, but rather, suggested a slight reduction that was not
statistically significant (1). They acknowledged that acute AT2-
receptor blockade is cardioprotective in the in vitro isolated
working heart model, where AT1-receptor blockade has a delete-
rious effect on recovery of contractile function (1,7). They recog-
nized that an AT1-receptor-mediated positive inotropic effect on
the myocardium is the most likely mechanism for this previously
reported improvement of contractile function with AT2-receptor
blockade after ischemia-reperfusion (7). This AT1-receptor-
mediated, nonvascular, second mechanism of cardioprotection
might be important and requires further study.
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